DDrare: Database of Drug Development for Rare Diseases

Searched query = "Dorabe syndrome", "Dravet syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Ataluren; CANNABIDIOL; CBD; CBD - Oral Solution, is known as Epidiolex, and is the approved name in the USA.; Cannabidiol; Cannabidiol (CBD); Cannabidiol Oral Solution; Carbidopa; Clemizole; Clobazam; DIACOMIT; DIACOMIT (Stiripentol); Diacomit; EPX-100 (Clemizole HCl); EPX-100 (Clemizole Hydrochloride); FENFLURAMINE HYDROCHLORIDE; FENFLURAMINE HYDROCHLORIDE (colorless); FENFLURAMINE HYDROCHLORIDE (red); FRISIUM*30CPS 10MG; Fenfluramina; Fenfluramina Cloridrato; Fenfluramine; Fenfluramine Hydrochloride; Fenfluramine hydrochloride; Fenfluramine hydrochloride (colorless); Fenfluramine hydrochloride (red); Frisium; GWP42003-P; GWP42003-P 10 mg/kg/day Dose; GWP42003-P 20 mg/kg/day Dose; GWP42003-P 5 mg/kg/day Dose; Levodopa; Lorcaserin; ME2080 (stiripentol); None; None at this time; Other antiepileptics; Placebo; Procedure: 12-Lead ECG; STK-001; Stiripentol; Stiripentolo; TAK-935; TOPAMAX; Topiramate; Turmeric; Verapamil; ZX008; ZX008 (Fenfluramine Hydrochloride); ZX008 - 0.2 mg/kg/day; ZX008 - 0.4 mg/kg/day; ZX008 - 0.8 mg/kg/day; ZX008 - 20 mg/day maximum dose; ZX008 0.2 and 0.8 mg/kg/day

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs041190116	17/02/2020	17/02/2020	3D gait analysis and L-DOPA in Dravet syndrome.	3D gait analysis and effectiveness of L-DOPA on pathological gait in Dravet syndrome.	Dravet syndrome(severe myoclonic epilepsy in infant) Dravet syndrome, severe myoclonic epilepsy in infant;D004831	Arm A:0) 3D gait analysis and RS-fMRI before medication 1) levodopa/carbidopa(5mg/kg/day or 300mg/day(more than 60kg)) given orally during 4-6weeks 2) second 3D gait analysis and RS-fMRI 3) reduce and stop medication durring 4weeks, no medication during 4-6weeks 4)third 3D gait analysis Arm B:0) 3D gait analysis and RS-fMRI before medication 1) 4-6weeks with no medication 2) second 3D gait analysis 3) levodopa/carbidopa given orally during 4-6weeks 4)third 3D gait analysis and second RS-fMRI	Natsume Jun	NULL	Recruiting	>= 6age old	Not applicable	Both	20	Phase 4	Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

JPRN-jRCTs041190116

17/02/2020

3D gait analysis and L-DOPA in Dravet syndrome.

3D gait analysis and effectiveness of L-DOPA on pathological gait in Dravet syndrome.

Dravet syndrome(severe myoclonic epilepsy in infant)
Dravet syndrome, severe myoclonic epilepsy in infant;D004831

Arm A:0) 3D gait analysis and RS-fMRI before medication 1) levodopa/carbidopa(5mg/kg/day or 300mg/day(more than 60kg)) given orally during 4-6weeks 2) second 3D gait analysis and RS-fMRI 3) reduce and stop medication durring 4weeks, no medication during 4-6weeks 4)third 3D gait analysis
Arm B:0) 3D gait analysis and RS-fMRI before medication 1) 4-6weeks with no medication 2) second 3D gait analysis 3) levodopa/carbidopa given orally during 4-6weeks 4)third 3D gait analysis and second RS-fMRI

Natsume Jun

NULL

Recruiting

>= 6age old

Not applicable

Both

Phase 4

Japan